Medtech developments over the Christmas period
The FDA scrambles for more rapid Covid-19 tests, and the device sector enjoys a late flurry of deals.
Aduhelm approval amplifies amyloid assays
Biogen needs blood tests for amyloid beta to progress quickly – and several are in the pipeline.
A lull in FDA Covid-19 test authorisations
Just as demand for coronavirus tests is peaking, the US regulator has a quiet week.
